Formulation and Evaluation of Floating Sustain Release Pellets of Anti Gout Drug

Upasana J. Patel a† and Hiteshkumar A. Patel b‡

a Nootan Pharmacy College, Sankalchand Patel University, Visnagar-384315, India.
b Department of Pharmaceutics, Nootan Pharmacy College, Sankalchand Patel University, Visnagar-384315, India.

Authors’ contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34952

Received 25 October 2021
Accepted 26 December 2021
Published 27 December 2021

ABSTRACT

Objective: The objective of this investigation was to formulate and evaluate effervescent pellets of febuxostat to achieve sustain release effect.

Place and Duration of Study: APMC College of Pharmaceutical education and research, Department of Pharmaceutics, Himatnagar-383001, between June 2019 and July 2021.

Materials and Methods: The gastro retentive effervescent pellets of febuxostat were formulated using Sodium CMC and HPMC K4M and HPMCK15M as a sustain release polymer. Pellets were prepared by extrusion- spherization technique using microcrystalline cellulose as spheronizing agent and sodium bicarbonate and citric acid as a gas forming agent for effervescent pellets. The pellets were characterized with respect to their floating lag time, total buoyancy time and % cumulative drug release.

Results and Discussion: DSC study showed that there was no change in the melting endotherm of the drug and drug-polymer mixture which means drug and polymers were compatible with each other. The optimized formulation B14 exhibits a floating lag time 4.00±0.004 sec. and cumulative % drug release at 12th hour 99.58±0.02. Scanning electron microscopy photomicrograph revealed that the surface was rough and pellets were spherical shaped in nature.
Conclusion: Febuxostat sustain release pellets was successfully formulated and evaluated as effervescent pellets with gas former agents and sustain release polymer HPMC K15.

Keywords: HPMC K15M; effervescent; febuxostat; floating.

1. INTRODUCTION

Due to considerable therapeutic advantages such as patient compliance, simplicity of patient administration, and formulation flexibility, oral dosage forms have been created throughout the last four decades [1]. The gastroretentive drug delivery system is an advanced approach to a revolutionary drug delivery system that keeps the medicine in the stomach for a long time [2,3]. Medications with a narrow absorption window, pharmaceuticals that act locally in a section of the gastrointestinal tract, drugs that are unstable in intestinal fluids, and drugs with poor solubility are all good candidates for the gastro retentive drug delivery system (GRDDS) [4,5]. The Oral dosage forms have been developed from the past four decades due to their significant therapeutic advantages such as patient compliance, ease of patient administration and flexibility in formulation articulate floating drug delivery system (FDDS) was preferred over a single-unit system due to minimum inter and intrasubject variability in drug absorption and lower possibility of dose dumping [6].

FDDS are low density systems, which allows them to remain buoyant in the stomach for a prolonged period. Effervescent systems are widely employed technology in the development of FDDS with buoyancy mechanism. In effervescent systems, carbon dioxide gas production occurs due to the reaction of bicarbonates and acid present in pellets, formed gas is entrapped in the polymers, which allows the systems to remain buoyant. The FDDS are efficiently used to design sustained drug delivery systems and improve the oral bioavailability of drugs [7-9].

Febuxostat is a 2- arylthiazole derivative, BCS class II drug having high permeability and low solubility. The Febuxostat decreasing serum uric acid by inhibiting xanthine oxidase with an in vivo inhibition k_i value less than one nanomolar and it potently inhibit both the oxidized and reduced forms of xanthine oxidase [12].

Although conventional oral dosage forms are widely used for the treatment of gout, but very poor bioavailability are observed in conventional dosage forms due to hepatic first pass metabolism.

Pellets, a multiparticulate system, offer various therapeutic and technological benefits over single-unit dose forms such as tablets. As a result, pelletizing febuxostat lowers the danger of dose dumping and ensures consistent medication distribution for up to 12 hours.

Hence, the objective of present work is to formulate and develop gastroretentive effervescent floating pellets of febuxostat using extrusion spheronization technique

2. MATERIALS AND METHODS

2.1 Materials

Febuxostat was obtained as a gift sample from Spentica life science, Rajkot. HPMC K15M, Sodium CMC and Microcrystalline cellulose was procured from qualichem, Vadodara. Citric acid was procured from purvi chemicals, Ahmedabad. All the studies were carried in distilled water.

2.2 Methods

2.2.1 Formulation of effervescent floating pellets

Floating pellets containing febuxostat were prepared using extrusion spheronization technique. The drug (80 mg), gas generating agent and pelletization aid quantity were mixed as per Table 1. Sufficient amount of PVP K15/K30/K90 was slowly added in the powder mixture to achieve a consistency of the damp mass suitable for further extrusion spheronization processes. The extrudate of uniform size was produced with the extruder. The
extrudate was then spheronized in a spheronizer with a rotation plate of regular cross hatch geometry for 10–15 min at a rotation speed of 1500 RPM. The resultant pellets were air dried for 15 min.

2.2.2 Evaluation of pellets

2.2.2.1 Calibration curve

Calibration curve was taken in 0.1 N hydrochloric acid for that dissolve 10 mg of drug in 100 ml of 0.1 N hydrochloric acid in a volumetric flask to get 100 μg/ml stock solution. This solution was further diluted to get solution in the concentration range of 1-10 μg/ml. Absorbance of these solution was determined spectrophotometrically at 314.87 nm (UV-1650, Pharmaspec, Shimadzu Ltd, Japan.)

2.2.2.2 Drug excipient compatibility study by Differential scanning calorimetry

Differential Scanning Calorimetry study were carried out with a differential scanning calorimeter (DSC 60 Shimadzu, Japan) under nitrogen flow. Samples each of 2 mg were accurately weighed using a santorius electronic microbalance and sealed in aluminum DSC pan and placed in the DSC cell. The DSC was previously calibrated for the temperature and enthalpy measurements in the standard way using melting of pure indium metal as a reference material. DSC runs were conducted over a temperature range of 50˚C to 300˚C at 10˚C /min under nitrogen flow rate of 40 ml/min. as reference empty aluminum pan was used.

2.2.2.3 Flow properties of pellets

For determination of flow from hopper to cavity used by using a funnel and calculated with equation 1, bulk and tapped density were calculated from bulk and tapped volume by using bulk and tapped density apparatus and by using those values Hausner’s ratio and Carr’s index were determined by equation 2 and 3.

Angle of repose \( \theta = \tan^{-1}\frac{h}{r} \) (1)

Where \( h \) = Height of pile and \( r \) = radius of the circle

Carr’s index = \( \frac{Tapped\ density-Bulk\ density}{Tapped\ density} \) (2)

Hausner’s ratio = \( \frac{Tapped\ density}{Bulk\ density} \) (3)

2.2.2.4 Particle size distribution

The particle size distribution of pellets was carried out by sieve analysis using mesh fractions 16/18, 18/20, 20/30, 30/44, and 44/60 for 5 min on a mechanical sieve shaker. The study was performed in triplicate for each batch of pellets.

Table 1. Formulation batches of effervescent pellets

| Batch | MC C | Na.CM C | NaHC O3 | HPMC K4 | HPMC K15 | PVP K15 | PVP K30 | PVP K90 | Citric acid |
|-------|------|---------|---------|---------|---------|---------|---------|---------|-------------|
| 1     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | 2.50%   | -       | -       | 0.3g        |
| 2     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | 5%      | -       | -       | 0.3g        |
| 3     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | 7.50%   | -       | -       | 0.3g        |
| 4     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | -       | 2.50%   | -       | 0.3g        |
| 5     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | -       | 5%      | -       | 0.3g        |
| 6     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | -       | 7.50%   | -       | 0.3g        |
| 7     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | -       | -       | 2.50%   | 0.3g        |
| 8     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | -       | -       | 5%      | 0.3g        |
| 9     | 2g   | 0.6g    | 0.9g    | 1.25g   | -       | -       | -       | 7.50%   | 0.3g        |
| 10    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | 2.50%   | -       | -       | 0.3g        |
| 11    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | 5%      | -       | -       | 0.3g        |
| 12    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | 7.50%   | -       | -       | 0.3g        |
| 13    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | -       | 2.50%   | -       | 0.3g        |
| 14    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | -       | 5%      | -       | 0.3g        |
| 15    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | -       | 7.50%   | -       | 0.3g        |
| 16    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | -       | -       | 2.50%   | 0.3g        |
| 17    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | -       | -       | 5%      | 0.3g        |
| 18    | 2g   | 0.6g    | 0.9g    | -       | 1.25g   | -       | -       | 7.50%   | 0.3g        |
2.2.2.5 Friability

Friability of the pellet formulations was determined using friabilator (Electrolab, Mumbai). 10 g of pellets were kept into friabilator and the percentage weight loss after 25 rpm for 4 min. was determined [13].

Friability = \frac{\text{Initial weight} - \text{final weight}}{\text{Initial weight}} \times 100 \quad (4)

2.2.2.6 Drug content

The drug content in each formulation was determined by taking floating pellets equivalent to about 100 mg of febuxostat, grounded and transferred into a volumetric flask containing 0.1 N HCl. The mixture was sonicated for 30 minutes to ensure complete extraction of drug in 0.1 N HCl. The solution was further filtered, diluted with appropriate amount of 0.1 N HCl and assayed spectrophotometrically at 314.187 nm [1,14,15]. (UV-1650, Pharmaspec, Shimadzu Ltd, Japan.) (n = 3).

% Drug content = \frac{\text{Weight of drug present in pellets (gm)} \times 100}{\text{Weight of quantity of pellets (gm)}}

2.2.2.7 Buoyancy study

The time between the introduction of the pellets into the medium and its buoyancy to the upper one third of the dissolution vessel (floating lag time) and the time for which the formulation constantly floated on the surface of the medium (floating duration) were measured simultaneously. The 100mg of pellets were placed in a beaker filled with 50 ml 0.1N HCl. Temperature was maintained at 37°C. The floating time of pellets was observed for 12hrs [15].

2.2.2.8 In vitro drug release studies

The drug release study was carried out using USP (type-II) paddle apparatus at 37 ± 0.5°C and at 50 rpm using 900 ml of 0.1N HCl as a dissolution medium (n=3). Accurately weighed pellets were placed in each vessel of dissolution apparatus. 10 ml of sample solution was withdrawn at predetermined time intervals, filtered, diluted suitably and analyzed spectrophotometrically. Equal amount of fresh dissolution medium was replaced immediately after withdrawal of the test sample. The cumulative percentage drug release was calculated for 12hr.

2.2.2.9 Surface morphology

Scanning electron microscopy is the technique of choice for measuring the shape, size and surface morphology of the pellets to support visually the other qualitative and quantitative results.

3. RESULTS AND DISCUSSION

3.1 Spectroscopic Studies

The λ max of febuxostat was found to be 314.87 nm. It obeyed Beer’s law in the range of conc. 2-10μg/ml. Linear regression of absorbance on concentration gave equation y=0.831x + 0.019 with a correlation coefficient of 0.998 in 0.1 N hydrochloric acid as indicated in Fig. 1.
3.2 Drug-excipient Compatibility Study by DSC

DSC is a thermodynamic analytical technique used to compare the thermal behavior of the pure drug and the combination of drug and excipients. The DSC thermogram of febuxostat showed sharp endothermic peak at 211.54°C shown in Fig. 2. The sharp endothermic peak was found near 200°C in DSC data of a mixture of febuxostat and excipients. The drug’s melting endothermic peak was clearly visible, with a minor change in peak broadening or sifting toward a lower temperature. Thus, slight changes in the melting endothermic peak of a medicine could be attributed to drug and excipient mixing, which affects the purity of each component in the mixture and may not necessarily indicate probable incompatibility. There was no change in the melting endotherm of the drug and drug-polymers mixture. Hence, it was concluded that drug and polymers are compatible with each other [Fig. 3].

3.3 Evaluation of Prepared Pellets

All batches of effervescent pellets were evaluated and obtained values indicated in Table 2. The angle of repose, carr’s index and hausner’s ratio values were within range specified. Thus all pellets were found to be stable for further evaluation.

Determination of % drug content

The results of %drug content was shown in Table 3. The values were in range 85.21±1.31 to 95.49±0.99. batch no. 2 and 10-18 were qualified for the further evaluation.

Fig. 2. Differential scanning calorimetry data of pure febuxostat

Fig. 3. Differential scanning calorimetry data of pure drug-mixture
Table 2. Evaluation of micromeric properties of pellets

| Batch | Bulk density (gm/ml) | Tapped density (gm/ml) | Carr’s index CI (%) | Hausner’s Ratio | Angle of repose |
|-------|----------------------|------------------------|---------------------|-----------------|-----------------|
| 1     | 1.02 ± 0.011         | 1.09 ± 0.012           | 12.70 ± 0.040       | 1.14 ± 0.04     | 26.73 ± 0.32    |
| 2     | 1.03 ± 0.011         | 1.06 ± 0.005           | 14.45 ± 1.89        | 1.13 ± 0.020    | 27.03 ± 0.09    |
| 3     | 1.08 ± 0.017         | 1.04 ± 0.014           | 15.15 ± 1.07        | 1.14 ± 0.012    | 26.85 ± 0.16    |
| 4     | 1.077 ± 0.011        | 1.08 ± 0.014           | 12.43 ± 1.06        | 1.14 ± 0.013    | 26.32 ± 0.32    |
| 5     | 1.078 ± 0.013        | 1.08 ± 0.01            | 13.42 ± 1.04        | 1.15 ± 0.013    | 26.03 ± 0.03    |
| 6     | 1.09 ± 0.012         | 1.1 ± 0.012            | 15.42 ± 1.88        | 1.14 ± 0.01     | 27.02 ± 0.09    |
| 7     | 1.08 ± 0.018         | 1.02 ± 0.017           | 12.13 ± 1.04        | 1.12 ± 0.01     | 27.01 ± 0.02    |
| 8     | 1.04 ± 0.019         | 1.01 ± 0.018           | 13.17 ± 1.85        | 1.13 ± 0.02     | 26.03 ± 0.02    |
| 9     | 1.06 ± 0.017         | 1.03 ± 0.019           | 15.87 ± 1.51        | 1.14 ± 0.03     | 27.96 ± 0.05    |
| 10    | 1.069 ± 0.013        | 1.04 ± 0.005           | 12.76 ± 0.55        | 1.15 ± 0.04     | 25.01 ± 0.01    |
| 11    | 1.09 ± 0.019         | 1.01 ± 0.017           | 13.11 ± 0.50        | 1.16 ± 0.06     | 25.53 ± 0.02    |
| 12    | 1.04 ± 0.029         | 1.05 ± 0.014           | 17.73 ± 0.95        | 1.17 ± 0.05     | 24.75 ± 0.03    |
| 13    | 1.04 ± 0.028         | 1.07 ± 0.019           | 17.73 ± 0.95        | 1.11 ± 0.04     | 23.02 ± 0.01    |
| 14    | 1.08 ± 0.018         | 1.01 ± 0.012           | 16.11 ± 0.50        | 1.02 ± 0.01     | 21.02 ± 0.02    |
| 15    | 1.06 ± 0.012         | 1.09 ± 0.014           | 15.76 ± 0.55        | 1.09 ± 0.04     | 22.02 ± 0.01    |
| 16    | 1.05 ± 0.015         | 1.12 ± 0.012           | 15.17 ± 1.85        | 1.11 ± 0.04     | 23.20 ± 0.03    |
| 17    | 1.01 ± 0.016         | 1.05 ± 0.01            | 12.42 ± 1.89        | 1.12 ± 0.05     | 24.02 ± 0.04    |
| 18    | 1.03 ± 0.010         | 1.03 ± 0.015           | 13.70 ± 0.040       | 1.14 ± 0.06     | 25.01 ± 0.01    |

Mean ±SD, n=3

Table 3. Evaluation of Friability, average particle size and drug content of pellets

| Batch | Friability (%) | Average particle Size (µm) | Shape | Drug Content (%) |
|-------|----------------|-----------------------------|-------|------------------|
| 1     | 0.74 ± 0.16    | 998                         | Oval  | 89.80 ± 1.69     |
| 2     | 0.72 ± 0.33    | 1100                        | Oval+ Spherical | 91.01 ± 1.55 |
| 3     | 0.73 ± 0.25    | 1010                        | Oval> Spherical | 88.96 ± 1.80 |
| 4     | 0.79 ± 0.013   | 1060                        | oval and long | 87.16 ± 1.96 |
| 5     | 0.82 ± 0.02    | 1069                        | Oval  | 89.80 ± 1.32     |
| 6     | 0.7 ± 0.01     | 1020                        | Oval+Spherical | 86.35 ± 1.58 |
| 7     | 0.92 ± 0.05    | 1100                        | Oval> Spherical | 88.47 ± 1.71 |
| 8     | 0.95 ± 0.02    | 1125                        | Oval and long | 87.38 ± 1.64 |
| 9     | 0.9 ± 0.07     | 1088                        | spherical>oval | 85.21 ± 1.31 |
| 10    | 0.53 ± 0.08    | 1225                        | spherical>oval | 93.61 ± 1.55 |
| 11    | 0.43 ± 0.16    | 1180                        | spherical>oval | 91.26 ± 1.46 |
| 12    | 0.51 ± 0.15    | 1175                        | spherical>oval | 90.72 ± 0.98 |
| 13    | 0.43 ± 0.14    | 1170                        | spherical | 91.26 ± 1.49 |
| 14    | 0.32 ± 0.01    | 1165                        | spherical | 95.49 ± 0.99 |
| 15    | 0.35 ± 0.02    | 1170                        | spherical>oval | 90.72 ± 0.97 |
| 16    | 0.37 ± 0.01    | 1078                        | spherical>oval | 93.57 ± 1.57 |
| 17    | 0.34 ± 0.03    | 1120                        | spherical>oval | 91.27 ± 1.89 |
| 18    | 0.33 ± 0.05    | 1220                        | spherical>oval | 91.01 ± 1.55 |

Mean ±SD, n=3

3.4 In Vitro Buoyancy Studies

In vitro buoyancy studies were performed on febuxostat pellets. The Floating lag time and total floating time of pellets are indicated in Table 4. As we change the polymer grade from HPMC K4M to HPMCK15M, the buoyancy lag time has been decreased. HPMC K15M with 5% PVPK30 concentration of binder provides maximum total floating time. According to data we optimized the batch having minimum floating lag time (Sec.) and maximum total floating time (hr.) and that was batch no. 14.

From all above evaluation, formulation batch having minimum floating lag time (4.00±0.004 sec.), maximum total floating time (11.5±0.03 hr.) and drug content (95.49±0.99%) optimized for in vitro drug release and surface morphology.
Table 4. Buoyancy test for various febuxostat formulations

| Batch | Floating lag time (sec) | Total floating time (hr) |
|-------|------------------------|--------------------------|
| 1     | 11.25±0.20             | 8.2±0.02                 |
| 2     | 12.26±0.19             | 7.25±0.04                |
| 3     | 13.08±0.11             | 7.55±0.07                |
| 4     | 10.16±0.23             | 7.16±0.01                |
| 5     | 8.25±0.20              | 9.5±0.04                 |
| 6     | 8.2±0.14               | 9.75±0.09                |
| 7     | 9.16±0.23              | 8.7±0.01                 |
| 8     | 10.33±0.31             | 7.6±0.06                 |
| 9     | 12.41±0.31             | 8.1±0.04                 |
| 10    | 5.38±0.27              | 8.27±0.02                |
| 11    | 6.33±0.23              | 9.05±0.02                |
| 12    | 6.38±0.30              | 8.2±0.01                 |
| 13    | 7.28±0.20              | 10.01±0.06               |
| 14    | 4.00±0.004             | 11.5±0.03                |
| 15    | 6.02±0.02              | 9.2±0.01                 |
| 16    | 6.01±0.08              | 8.5±0.07                 |
| 17    | 7.2±0.14               | 7.15±0.01                |
| 18    | 7.26±0.19              | 7.25±0.4                 |

Mean ±SD, n=3

Fig. 4. Dissolution profile of optimized formulation

4. EVALUATION OF OPTIMIZED BATCH

In vitro dissolution studies

Surface Topography (SEM analysis)

Photomicrographs of pellets [Fig. 5] revealed that the surface was rough and the pellets were spherical in nature, which having size less than 1 mm, were taken using a scanning electron microscope (JSM7600F Joel, Tokyo, Japan) for visualization of pellet surface morphology.
5. CONCLUSION

The Effervescent floating pellets of febuxostat was prepared and evaluated successfully by extrusion spheronization method using gas generating agent and sustain release polymer. It was found that change in polymer grade and concentration of binder- PVP, also change in buoyancy lag time and total floating time. It was concluded that HPMC K15M with 5% PVP K30 binder concentration provide maximum total floating time and minimum lag time. The optimized formulation batch no. 14 showed drug release of 98.54% within 12 h. SEM study near to 1mm confirmed that the prepared formulation was spherical in nature.

CONSENT

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

REFERENCES

1. Patel K. Formulation and evaluation of gastroretentive floating pellets of nizatidine. Asian J Pharm. 2020;14(4):513-524.
2. Singh B, Kim K. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63:235-59.
3. Lopes C, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive
drug delivery systems for improving drug bioavailability. Int J Pharma. 2016;510:44-58.
4. Mandal U, Chatterjee B, Senjoti F. Gastro-retentive drug delivery systems and their in vivo success: A recent update. Asian J Pharma Sci. 2016;11:575-84.
5. Salve V, Mishra R, Nandgude T. Development and optimization of a floating multiparticulate drug delivery system for norfloxacin. Turk J Pharm Sci. 2019;16:326-34.
6. Bulgarelli E, Forni F, Bernabei M. Effect of matrix composition and process conditions on casein-gelatin beads floating properties. Int J. Pharm. 2000;198:327-33.
7. Sharma AR, Khan A. Gastroretentive drug delivery system: An approach to enhance gastric retention for prolonged drug release. Int J Pharma Sci Res. 2014;5:1095-1106.
8. Narang N. An updated review on: Floating drug delivery system (FDDS). Int J. Applied Pharma. 2011;3:1-7.
9. Thahera PD, Latha K, Shailaja T, Nyamathulla S, Uhumwangho MU. Formulation and evaluation of Norfloxacin gastro retentive drug delivery systems using natural polymers. Int Current Pharma J. 2012;1:155-164.
10. Frampton JE. Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout. Drugs. 2015;75(4):427-38.
11. Love BL, Barrons R, Veverka A, Snider KM. Urate-lowering therapy for gout: Focus on febuxostat. Pharmacotherapy. 2010;30(6):594–608.
12. Patel RH. Development and optimization of immediate release tablet of febuxostat in gout treatment. AJPER. 2018;6(1):16-25.
13. Gupta V, Gowda D, Balamuralidhara V, Khan S. Formulation and evaluation of olanzapine matrix pellets for controlled release. Daru. 2011;19:32-42.
14. Mishra RV, Dhole SN. Lipid-based floating multiparticulate delivery system for bioavailability enhancement of berberine hydrochloride. Journal of Applied Pharmaceutical Science. 2019;9(11):036-047.
15. Nowshad S, Pathan S. Preparation and evaluation of gastroretentive floating pellets of metronidazole. Bangladesh Pharmaceutical Journal. 2013;16(1):107-115.

Peer-review history:
The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/80382